CN112494430B - 药物组合物的制备方法及药物组合物 - Google Patents

药物组合物的制备方法及药物组合物 Download PDF

Info

Publication number
CN112494430B
CN112494430B CN202010954970.0A CN202010954970A CN112494430B CN 112494430 B CN112494430 B CN 112494430B CN 202010954970 A CN202010954970 A CN 202010954970A CN 112494430 B CN112494430 B CN 112494430B
Authority
CN
China
Prior art keywords
cellulose
pharmaceutical composition
pharmaceutical
water
cnc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010954970.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN112494430A (zh
Inventor
M·诺珀宁
黄翔
宋秋海
王玉珑
刘艳新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UPM Kymmene Oy
Original Assignee
UPM Kymmene Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UPM Kymmene Oy filed Critical UPM Kymmene Oy
Publication of CN112494430A publication Critical patent/CN112494430A/zh
Application granted granted Critical
Publication of CN112494430B publication Critical patent/CN112494430B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202010954970.0A 2019-09-13 2020-09-11 药物组合物的制备方法及药物组合物 Active CN112494430B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19397527.3 2019-09-13
EP19397527.3A EP3791864A1 (en) 2019-09-13 2019-09-13 Method for preparing pharmaceutical composition and pharmaceutical composition

Publications (2)

Publication Number Publication Date
CN112494430A CN112494430A (zh) 2021-03-16
CN112494430B true CN112494430B (zh) 2023-06-02

Family

ID=67997550

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010954970.0A Active CN112494430B (zh) 2019-09-13 2020-09-11 药物组合物的制备方法及药物组合物

Country Status (5)

Country Link
US (1) US11723867B2 (OSRAM)
EP (1) EP3791864A1 (OSRAM)
JP (1) JP7640065B2 (OSRAM)
KR (1) KR20210032280A (OSRAM)
CN (1) CN112494430B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3791858A1 (en) 2019-09-13 2021-03-17 UPM-Kymmene Corporation Injectable pharmaceutical formulation
JP2021090881A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090879A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090883A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090884A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090882A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
CN116764001B (zh) * 2023-06-29 2025-11-11 上海交通大学医学院附属第九人民医院 多孔碳基双载药纳米缓释材料及其子宫支架与应用
WO2025155702A1 (en) * 2024-01-19 2025-07-24 University Of Maine System Board Of Trustees Cellulose-based hydrogels as vaccine adjuvants
CN119528842B (zh) * 2024-10-25 2025-12-16 上海工程技术大学 一种通过氧化纳米纤维素调控药物晶型的方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4308336B2 (ja) * 1997-03-14 2009-08-05 株式会社日本吸収体技術研究所 ミクロフィブリル状微細繊維構造体およびその製造方法
CA2325386C (en) 1999-01-28 2010-03-23 Hydromed Sciences A Division Of Gp Strategies Corporation Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
FI20095638A0 (fi) 2009-06-09 2009-06-09 Valtion Teknillinen Hydrofobiineja aktiivisten aineiden dispergointiin
FI123988B (fi) 2010-10-27 2014-01-31 Upm Kymmene Corp Soluviljelymateriaali
FI130619B (en) * 2011-11-15 2023-12-15 Upm Kymmene Corp Matrix for sustained delivery of bioactive agents
CN105007898A (zh) * 2012-12-19 2015-10-28 卡希夫制药有限责任公司 难溶性药物的过饱和的稳定纳米颗粒
FI126109B (en) 2013-02-22 2016-06-30 Upm Kymmene Corp Nanofibril polysaccharide for use in the control and prevention of constriction and scarring
CN103520739B (zh) 2013-10-22 2015-01-28 东北林业大学 一种纤维素纳米纤丝和吲哚美辛自组装复合体系的制备方法
FI126854B (en) * 2013-12-30 2017-06-30 Upm Kymmene Corp The membrane, its use and the method for making the membrane
JP6712875B2 (ja) * 2016-03-04 2020-06-24 第一工業製薬株式会社 繊維芽細胞増殖促進剤
DK3922279T3 (da) 2016-08-30 2025-02-03 Dana Farber Cancer Inst Inc Præparater til lægemiddelafgivelse og anvendelse heraf
EP3791858A1 (en) 2019-09-13 2021-03-17 UPM-Kymmene Corporation Injectable pharmaceutical formulation

Also Published As

Publication number Publication date
JP7640065B2 (ja) 2025-03-05
EP3791864A1 (en) 2021-03-17
CN112494430A (zh) 2021-03-16
JP2021046392A (ja) 2021-03-25
US20210077403A1 (en) 2021-03-18
KR20210032280A (ko) 2021-03-24
US11723867B2 (en) 2023-08-15

Similar Documents

Publication Publication Date Title
JP7640065B2 (ja) 医薬組成物を調製する方法及び医薬組成物
Wang et al. Fabrication and characterization of chitin nanofibers through esterification and ultrasound treatment
Deng et al. Cellulose nanofibril as a crosslinker to reinforce the sodium alginate/chitosan hydrogels
Liu et al. Effects of ultrasonication on the properties of maize starch/stearic acid/sodium carboxymethyl cellulose composite film
Rostamabadi et al. Cellulose nanofibers, nanocrystals, and bacterial nanocellulose: Fabrication, characterization, and their most recent applications
Lin et al. Supramolecular hydrogels from in situ host–guest inclusion between chemically modified cellulose nanocrystals and cyclodextrin
Daus et al. Xylan‐based nanoparticles: Prodrugs for ibuprofen release
Padil et al. Dodecenylsuccinic anhydride derivatives of gum karaya (Sterculia urens): Preparation, characterization, and their antibacterial properties
JP7069484B2 (ja) 注射可能な医薬製剤
Kloser et al. Surface grafting of cellulose nanocrystals with poly (ethylene oxide) in aqueous media
Koshani et al. Characterization of carboxylated cellulose nanocrytals isolated through catalyst-assisted H2O2 oxidation in a one-step procedure
Hettrich et al. Novel aspects of nanocellulose
JP2002536507A (ja) 誘導微小繊維ポリサッカライド
Gabriel et al. Valorization of khat (Catha edulis) waste for the production of cellulose fibers and nanocrystals
Yan et al. Influence of esterification and ultrasound treatment on formation and properties of starch nanoparticles and their impact as a filler on chitosan based films characteristics
Moreau et al. Bifunctionalization of cellulose fibers by one-step Williamson’s etherification to obtain modified microfibrillated cellulose
Li et al. Melatonin loaded with bacterial cellulose nanofiber by Pickering-emulsion solvent evaporation for enhanced dissolution and bioavailability
Vanhatalo et al. Microcrystalline cellulose property–structure effects in high-pressure fluidization: microfibril characteristics
Cabrera-Barjas et al. Effect of cellulose nanofibrils on vancomycin drug release from chitosan nanocomposite films
Torlopov et al. A Fenton-like system (Cu (II)/H2O2) for the preparation of cellulose nanocrystals with a slightly modified surface
Chinga-Carrasco et al. Carboxylated nanocellulose for wound healing applications–Increase of washing efficiency after chemical pre-treatment and stability of homogenized gels over 10 months
JP2018002668A (ja) ゲル状シート組成物およびその製造方法
Luo et al. The influence of residual pectin composition and content on nanocellulose films from ramie fibers: Micro-nano structure and physical properties
Ogura et al. Effect of gamma irradiation on cellulose nanofibers
Gao et al. From agro-waste to functional emulsifiers: length-optimized cellulose nanocrystals from jujube seeds enhance curcumin delivery in pickering emulsions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant